RISPERIDONE EFFECTS IN TREATMENT-RESISTANT ADOLESCENTS - PRELIMINARY CASE-REPORTS

被引:54
作者
SIMEON, JG
CARREY, NJ
WIGGINS, DM
MILIN, RP
HOSENBOCUS, SN
机构
[1] Institute of Mental Health Research, Royal Ottawa Hospital, Ottawa, Ontario, Canada
[2] Royal Inland Hospital, Kamloops, British Columbia, Canada
关键词
D O I
10.1089/cap.1995.5.69
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Many children and adolescents with a variety of chronic psychiatric disorders receive long-term therapy with antipsychotic medications, Clinical case reports are presented of seven such adolescents, aged 11-17 years, who were treated with risperidone, All but one patient had prior unsuccessful treatments with various psychotropic medications, The use of risperidone seemed effective in six of the seven adolescents in a dose range of 1-4 mg daily,with a significant therapeutic response appearing in 1 to 3 weeks, The length of risperidone treatment ranged from 3 to 15 months, Some sedation/drowsiness was observed in two patients at the maximum recommended adult dose (6 mg/day), but this was resolved by a reduction in the daily dosage, There were no other significant adverse effects, including extrapyramidal reactions, Two adolescents received concomitant medication, including d-amphetamine and clomipramine, Risperidone appeared to be effective in relieving a variety of symptoms across a range of diagnoses, including schizophrenia, pervasive developmental disorder (PDD), and attention deficit disorder (ADD), but not obsessive compulsive disorder (OCD), Risperidone administration seemed most useful in treating paranoid ideation, aggressive and impulsive behavior, and mood swings, Controlled studies are needed to determine the efficacy and safety of risperidone in adolescents, If risperidone proves to be safe and effective over the long term; then clinicians may have a relatively nontoxic ''antipsychotic'' agent that could relieve disabling symptoms in nonpsychotic as well as psychotic children and adolescents.
引用
收藏
页码:69 / 79
页数:11
相关论文
共 16 条
[1]  
Addington D.E., Jones B., Bloom D., Chouinard G., Remington G., Albright P., Reduction of hospital days in chronic schizophrenic patients treated with risperidone: Retrospective study, Clin Ther, 15, pp. 917-926, (1993)
[2]  
Borison R.L., Pathiraja A.P., Diamorid B.I., Meibach R.C., Risperidone: Clinical safety and efficacy in schizophrenia, Psychopharmacol Bull, 28, pp. 213-218, (1992)
[3]  
Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Amott W., A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients, J Clin Psychopharmacol, 13, pp. 20-25, (1993)
[4]  
Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S., Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study, Acta Psychiatr Scand, 85, pp. 295-305, (1992)
[5]  
Conners C.K., Conners’ Rating Scales Manual, Toronto, Multi-Health Systems, Inc., (1989)
[6]  
Cozza S.J., Edison D.L., Risperidone in adolescents [Letter], J Am Acad Child Adolesc Psychiatry, 33, (1994)
[7]  
Dwight M.M., Keck P.E., Stanton S.P., Strakowski S.M., McEIroy S.L., Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder, Lancet, 344, pp. 554-555, (1994)
[8]  
Goodnick P.J., Risperidone treatment of refractory acute mania, J Clin Psychiatry, (1995)
[9]  
Marder S.R., Risperidone: Clinical development: North American results, Clin Neuropharmacol, 15, 1, pp. 92A-93A, (1992)
[10]  
Marder S.R., Meibach R.C., Risperidone in the treatment of schizophrenia, Am J Psychiatry, 151, pp. 825-835, (1994)